The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Hecht Beth since 2019.
This trader's CIK number is 1652410.
At the time of last reporting, Hecht Beth was the See Remarks of Xeris Biopharma Holdings, Inc.. (stock ticker symbol XERS).
Also see all insider trading activities at Xeris Biopharma Holdings, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | XERS | 8,000 | $24,480 | 0 | $0 | 0 | $0 |
| 2019 | XERS | 2,500 | $25,000 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | XERS | 0 | $0 | 40,000 | $217,240 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | ITRM | 0 | $0 | 0 | $0 | 15,853 | $0 |
| 2022 | ITRM | 0 | $0 | 0 | $0 | 44,440 | $0 |
1. Xeris Pharmaceuticals Inc (XERS)
2. Xeris Biopharma Holdings, Inc. (XERS)
3. Iterum Therapeutics Plc (ITRM)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-03-13 | XERS | Buy | 4,000 | 1.97 | 7,880 |
| 2020-02-14 | XERS | Buy | 4,000 | 4.15 | 16,600 |
| 2019-02-19 | XERS | Buy | 2,500 | 10.00 | 25,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-20 | XERS | Sale | 40,000 | 5.43 | 217,240 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-06-15 | ITRM | Option Ex | 15,853 | .00 | 0 |
| 2022-06-23 | ITRM | Option Ex | 36,798 | .00 | 0 |
| 2022-03-18 | ITRM | Option Ex | 7,642 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hecht Beth (See Remarks of Xeris Biopharma Holdings, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.